Bosnia's building permits up 5.8% y/y in Jan
Bosnia's Federation building permits down 2.7% y/y in Jan
Agri goods' producer prices in Croatia down 3% y/y in 2023
Romanian stock indices start week in the green, Purcari Wines shines
Sofia share indices close mixed, Fibank paces blue-chip decliners
Nov 18, 2022 15:54 EEST
November 18 (SeeNews) - Slovenian pharmaceutical products wholesaler Salus [LJE:SALR] has extended the validity of its binding offer for the purchase of 75% of the equity capital of local sector player Farmadent to December 15, Salus said on Friday.
Negotiations are still ongoing and the validity of the binding offer has been extended until December 15, Salus said in a filing with the Ljubljana Stock Exchange.
You can subscribe to our M&A newsletter here
Salus submitted a binding bid for the purchase of the stake in Farmadent on September 24 and set October 19 as a deadline for the validity of its offer but later postponed it to November 3 and then to November 18.
The bid includes an option for the purchase of the remaining 25% stake in Farmadent, or alternatively the company's entire capital.
The potential acquisition of Farmadent is in line with Salus' development strategy, which envisages the expansion of activities in regions where the company is not yet present.
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options